“The Portage model has the same goal, which is to get to human proof-of-concept as quickly as possible,” says Walters. “

“We’re in a steel mill town,” Keir Loiacono, chief executive officer at BlueSphere Bio told BioSpace. “I can look from my office out of the glass buildings and see coal barges going through, right next to young scientists in lab coats. It’s the old and the new – it’s everybody working together.”

An anti-CD70 antibody-drug conjugate developed by Ambrx, Inc. has been administered to the first patient in a Phase I study in China. It marks the first ADC in active development that targets CD70, according to the company.

In this video from ASN Kidney Week, Jonathan Barratt, MBChB, PhD, discusses Calliditas Therapeutics’ Tarpeyo treatment, previously known as Nefecon, for patients with IgA nephropathy.

TFF Pharmaceuticals is advancing this technique as a platform technology for improving the formulation of complex modalities, including vaccines, small molecules and biologics, as dry powders. According to Hannon, this approach provides key advantages, including access to more convenient routes of administration due to aerosolization properties (i.e., inhalation or intranasal delivery) and elimination of the need for ultra-cold chain storage due to temperature stability.

The Thin Film Freezing technology, invented by Dr. Williams and his team and advanced by Fort Worth-based TFF Pharmaceuticals, is developed via a well controlled process that involves rapid freezing and drying drugs into a powder.

MIT-born startup Elicio Therapeutics’ novel Amphiphile Technology Platform is designed to directly engage the lymphatic system in the deployment and delivery of therapeutic payloads.

Fungal infections kill more than 1.6 million people yearly, according to Global Action for Fungal Infections, a research and fundraising organization. The toll is climbing. Fungi are adapting to rising temperatures in ways that may make them better suited to thrive in the human body, researchers said. And more people undergoing treatments that weaken their immune systems means a larger population vulnerable to severe fungal infections.